Inflammatory bowel disease comorbid with autoimmune liver disease
- VernacularTitle:炎症性肠病合并自身免疫性肝病
- Author:
Yinghao SUN
1
;
Jiaming QIAN
1
Author Information
- Publication Type:Journal Article
- Keywords: Autoimmune Diseases; Inflammatory Bowel Disease; Therapeutics
- From: Journal of Clinical Hepatology 2025;41(7):1256-1260
- CountryChina
- Language:Chinese
- Abstract: The coexistence of inflammatory bowel disease(IBD)and autoimmune liver disease(AILD)has gained increasing attention in clinical practice,and there are significant increases in the prevalence rates of autoimmune hepatitis(AIH),primary sclerosing cholangitis(PSC),and AIH-PSC overlap syndrome among the patients with IBD.Several pathogenic mechanisms are shared between IBD and AILDs,including genetic susceptibility,dysregulation of the gut-liver axis,immune imbalance,and abnormal bile acid metabolism.The ECCO guidelines recommend that patients who are suspected of IBD and receive no treatment should undergo a series of liver function tests,including alanine aminotransferase,alkaline phosphatase,gamma-glutamyl transferase,and total serum bilirubin,as well as regular reexaminations during follow-up.While IBD-AILD patients have unique clinical features,there is still a lack of unified diagnosis and treatment guidelines for this comorbidity,and the selection of therapeutic goal often entails a careful balance between the intestinal tract and the liver,requiring interdisciplinary collaboration and combined therapies based on pathogenesis.Future research should focus on the dynamic regulatory networks of the gut-liver axis to develop innovative intervention strategies that ensure both efficacy and safety.
